Imetelstat Sodium Patent Expiration
Imetelstat Sodium was first introduced by Geron Corp
Imetelstat Sodium Patents
Given below is the list of patents protecting Imetelstat Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rytelo | US12171778 | Methods of treating myelodysplastic syndrome | Jun 16, 2039 | Geron |
| Rytelo | US12442000 | Use Of Telomerase Inhibitors For The Treatment Of Myeloproliferative Disorders And Myeloproliferative Neoplasms | Mar 15, 2033 | Geron |
| Rytelo | US9375485 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | Mar 15, 2033 | Geron |
| Rytelo | US7494982 | Modified oligonucleotides for telomerase inhibition | Dec 27, 2026 | Geron |
| Rytelo | US9388415 | Modified oligonucleotides for telomerase inhibition |
Sep 09, 2026
(Expired) | Geron |
| Rytelo | US9388416 | Modified oligonucleotides for telomerase inhibition |
Sep 09, 2026
(Expired) | Geron |
Imetelstat Sodium's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Imetelstat Sodium:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | Geron Corporation | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |